#67 - AMA #8: DNA tests, longevity genes, metformin, fasting markers, salt, inflammation, and more

Published: Aug. 19, 2019, 9:30 a.m.

In this \u201cAsk Me Anything\u201d (AMA) episode, Peter answers a wide range of questions from subscribers. Bob Kaplan, Peter\u2019s head of research, asks the questions. If you\u2019re not a subscriber and listening on a podcast player, you\u2019ll only be able to hear a preview of the AMA.

If you\u2019re a subscriber, you can now listen to this full episode on your\xa0private RSS feed. You can also watch (or listen) to this full episode on our website at the AMA #8\xa0show notes page.

Questions continue to be pulled from the\xa0AMA section\xa0on the website, and any subscriber is welcome to submit questions for future AMAs.

We discuss:

  • Do DNA kits provide actionable info for cancer, CVD, diabetes, Alzheimer\u2019s, nutrition, or exercise? [1:45];
  • What genes increase longevity? And do those genes show up on genetic tests like 23andMe? [12:00];
  • Who are some people that Peter would like to have as guests on The Drive? [15:00];
  • Inflammation: Is CRP a useful marker? What can one do to reduce it? And what other inflammatory markers can I look at to gauge health? [18:30];
  • What lipid test does Peter now use on his patients? What are the three best cardiovascular laboratories? [28:00];
  • Metformin for longevity: What considerations should one think about before doing taking metformin for longevity purposes? [32:30];
  • What is Peter\u2019s take on salt and its role in things like high blood pressure and stomach cancer? [40:00];
  • What markers does Peter find most interesting (and surprising) during his quarterly fasts? [47:30]; and
  • More.

Learn more:\xa0https://peterattiamd.com/

Show notes page for this episode:http://peterattiamd.com/ama08

Subscribe to receive exclusive subscriber-only content:\xa0https://peterattiamd.com/subscribe/

Sign up to receive Peter's email newsletter:\xa0https://peterattiamd.com/newsletter/

Connect with Peter on Facebook | Twitter | Instagram.